A review of the off-label use of selamectin (Stronghold®/Revolution®) in dogs and cats

Maggie A Fisher*1 and David J Shanks2

Address: 1Shernacre Enterprise, Shernacre Cottage, Lower Howsell Road, Malvern, Worcs WR14 1UX, UK and 2Peuman, 16350 Vieux Ruffec, France

Email: Maggie A Fisher* - mfisher@globalnet.co.uk; David J Shanks - davidjohnshanks@gmail.com

* Corresponding author

Abstract
Since its introduction approximately seven years ago, selamectin (Stronghold®/Revolution®, Pfizer Inc.) has been used off-label to treat a number of ecto- and endoparasite conditions in dogs and cats. It has been used as a successful prophylactic against Dirofilaria repens and as a treatment for Aelurostrongylus abstrusus in cats. It has also been used to treat notoedric mange, infestation with the nasal mite Pneumonyssoides caninum, Cheyletiella spp. and Neotrombicula autumnalis infestations and larval Cordylobia anthropophaga infection. However, to date attempts to treat generalised canine demodicosis have not been successful. In all cases, treatment was apparently well tolerated by the host.

Background
Until relatively recently, the antiparasitic products available to the veterinarian were often inadequate [1]. During the last two or three decades however, remarkable progress has been achieved in some areas of parasite control through better understanding of the behaviour and life cycles of the target parasites and the introduction of a new generation of antiparasitics [1,2]. By the end of the last decade of the twentieth century avermectins (for example ivermectin and doramectin) and milbemycins (for example moxidectin), because of their activity against both endoparasites and ectoparasites, had become well established as endectocides for the treatment of livestock. The development of the equivalent products for cats and dogs evolved more slowly, perhaps because companion animals were not the priority for pharmaceutical development initially. The first avermectin-based product approved for use in companion animals was a low-dosage formulation of ivermectin solely for the prevention of adult heartworm (Dirofilaria immitis) infestations in dogs [3]. Higher doses of ivermectin, which might have provided a broader spectrum of activity allowing control of more parasite species, were unattainable because of idiosyncratic toxic reactions in some breeds of dog [4]. Thereafter a systematic programme to evaluate avermectin analogues resulted in the discovery of the macrocyclic lactone selamectin, which was shown to have efficacy and safety profiles which warranted its commercialisation for cats and dogs [5].

During the pre-development evaluation of the safety and efficacy of selamectin in dogs and cats, the compound was administered topically and orally at various intervals and dosages and its efficacy against target endo-and ectoparasites was assessed. In studies conducted early in the discovery and development process, selamectin was administered orally in some studies and topically in others. These studies demonstrated conclusively the efficacy of the compound, when applied topically, against both endoparasites (larval Dirofilaria immitis), and against...
ectoparasites (*Ctenocephalides felis*); oral administration showed activity against a range of parasites: *Ancylostoma caninum*, *A. tubaeforme*, *Toxocara canis*, *T. cati*, *Uncinaria stenoecephala*, *Toxascaris leonina*, *Rhipicephalus sanguineus caninum*, *A. tubaeforme*, *Toxocara canis*, *T. cati*, *Uncinaria* showed activity against a range of parasites:

Table 1: Summary of label claims for selamectin in Europe

| Dogs and cats: |  |
|---|---|
| Treatment and prevention of flea (*Ctenocephalides spp.*) infestations including use as part of a treatment strategy for flea allergy dermatitis and may assist in the control of existing environmental flea infestations in areas to which the animal has access |  |
| Treatment of ear mite (*Otodectes cynotis*) infection |  |
| Heartworm (*Dirofilaria immitis*) prevention |  |

**Dogs for the treatment of:**

*Adult Toxocara canis*

*Sarcoptes scabiei* (sarcoptic mange mites)

*Trichodectes canis* (biting lice)

**Cats for the treatment of:**

*Adult Toxocara cati*

*Adult hookworm (*Ancylostoma tubaeforme*)

*Felicola subrostratus* (biting lice)
*Aelurostrongylus abstrusus* infects the lungs of cats and has a worldwide distribution; in areas where the infection is endemic up to 90% of cats may be infected [14,15]. Infection may be asymptomatic or may cause clinical signs, typically including severe coughing and respiratory distress. These are non-specific signs but diagnosis can be confirmed by examination of faeces or tracheal washings for infective larvae. In a case report [14], a six-month old domestic cat presented with a three-month history of dyspnoea, and aelurostrongylosis was diagnosed by the identification of first stage larvae in tracheal washings. The cat was treated with selamectin topically at 18 mg/kg and within two days clinical signs had receded and five weeks after the initiation of treatment (one week after a second application of selamectin at the same dose-rate) respiration was markedly improved and radiographic signs of bronchial disease were not evident. Selamectin at a dose-rate of 6 mg/kg was effective in one out of three cats on the basis of the elimination of larvae from the faeces after 30 days [16]. To date, reports of the use of selamectin to treat lungworm in dogs have not been published and it may be that selamectin is not useful in the treatment of lungworms in dogs, given the lower bioavailability of selamectin in dogs [10].

**Ectoparasites**

Selamectin shows activity against both insect and arachnid classes of ectoparasites, and is licensed to treat sarcotic mange and *Otodectes cynotis* infestations. As historically there has been a lack of effective miticidal treatments, and a greater lack of licensed miticidal treatments, unsurprisingly selamectin has been used against a number of mite infestations for which it does not have a label claim and has been demonstrated to possess useful activity against some species.

Notoedric mange is a highly contagious, pruritic cutaneous mite infestation of kittens, cats and occasionally rabbits, dogs and pine civets caused by the psoroptic mite *Notoedres cati* [17,18]. The infestation is clinically characterised by extreme pruritus and crustous lesions of the ears, head, neck, back and feet. *N. cati* is easily transmitted between animals and therefore a simple and reliable treatment must be rapidly applied to infested patients. A single administration of selamectin at the recommended dose (6 mg/kg) has been successfully used to eliminate the mites [17,18]. The success of a single treatment administered to cats in cases where eggs were evident at treatment suggests that selamectin has an extended duration of activity against *N. cati* in cats [17].

*Pneumonyssoides caninum*, the nasal mite of dogs, dwells in the caudal nasal cavity and paranasal sinuses of dogs causing non-specific signs of upper respiratory tract disease such as sneezing, reverse sneezing, epistaxis and impaired scenting ability [19]. The mite occurs worldwide but is particularly common in Scandinavia, where 20% of dogs in Sweden were found to be infected in a post-mortem survey [19]. Diagnosis in the living dog is difficult as the mites do not inhabit the easily visualised part of the nasal cavity, and in Scandinavia dogs with appropriate clinical signs are frequently treated presumptively. Gunnarsson and others [19] reported a controlled trial where six dogs infected with *P. caninum* were treated topically with selamectin on three occasions at fortnightly intervals at doses from 6 to 24 mg/kg. At post mortem examination between 33 and 35 days after treatment no mites were found in any treated dog, whilst five of six untreated controls had live mites.

One of the most striking clinical descriptions of an ectoparasite infestation of dogs, cats and rabbits is “walking dandruff”, which may be observed on pups with a heavy infestation of *Cheyletiella* spp. This sign is caused by the movement of these rather large mites under “the branlike exfoliative debris” [20] which occurs as a result of infestation [21]. *Cheyletiella* is highly contagious [21,22], particularly when a number of animals live together, as for example in breeding colonies [22] and is caused by *C. parasitivorax*, *C. blakei* or *C. yasguri*. *Cheyletiella* mites are not host specific [21,23], moving readily between dogs, cats and rabbits, and can survive for at least 10 days off the host in the environment under suitable conditions [21]. Infestation can occur by direct transmission of the parasite or via fomites, and the infestation is zoonotic [23]. Traditionally, infections were treated by weekly applications of various topical acaricidal products [21], with all the inconvenience and disturbance that such treatment regimens entail. Recently, selamectin administered topically has been demonstrated to be a highly effective treatment for *cheyletiellosis* in rabbits, cats and dogs [22]. Fifteen cats infested with *Cheyletiella* spp. and two uninfested dogs that lived in the same household were treated with between 6 and 15 mg, with a mean dose of 9 mg/kg selamectin/kg on days 0, 30 and 60 [21]. On day 120 no cat showed evidence of infestation and, during the follow-up of one year, re-infestation from environmental contamination or fomites did not occur, indicating that the infestation had been completely eliminated from the household. All 38 dogs in two households where persistent *Cheyletiella* sp. infestation had been identified were treated [22]. Dogs were treated with selamectin at a dose-rate of between 6 and 12 mg/kg at fortnightly intervals on a total of four occasions using the standard unit dosing tubes. Pruritus diminished following treatment and did not recur during a one year follow-up period. Although it cannot be proven that selamectin resulted in parasitological cure in these cases, administration at the stated dose rates appears able to resolve clinical signs of *cheyletiellosis* in dogs and cats.
Eight cats naturally infested with the harvest mite *Neotrombicula autumnalis* were treated with selamectin at 6 mg/kg and two days later the clinical signs associated with the infection had subsided and all mites were dead [24].

*Demodex* spp. are tiny, "cigar-shaped" mites which live in the hair follicles and sebaceous glands of mammals. Most infections are not associated with any clinical disease and it is not until much larger than normal populations infest the host, probably due to genetic characteristics or immunodeficiency of the host or to concomitant disease, that clinical manifestation of the infestation occurs [25]. In localised infestations on dogs, circumscribed areas of erythema and alopecia appear typically around eyes, mouth and on the forelegs; infestations which remain thus localised may self-cure [25] making it difficult to evaluate time efficacy of a product against localised infestations. However, the infestation may become persistent and generalised, with the hair becoming sparse over multiple areas of the body or feet, and in these cases the response to treatment may be poor. Attempts have been made to treat the generalised form of canine demodicosis with selamectin, applied both as recommended on the label and more frequently than recommended, applied to the recommended application site or directly to the visible lesions, but without success [26]. No improvement was seen in a Japanese Chin with generalised demodicosis which had previously proved unresponsive to ivermectin therapy when treated with selamectin once daily for two weeks at 30 mg/kg [27].

*Cordylobia anthropophaga* is found in Africa and is a myiasis-causing fly belonging to the family *Calliphoridae*. The adult *C. anthropophaga* or Tumbu fly lays eggs in the environment. When these larvae (the Cayor worm) hatch they remain in the environment until they sense a host, to which they rapidly attach prior to burrowing into the tissues. The larva develops subcutaneously with a single pore to the outside. It is a common cause of cutaneous myiasis in dogs in tropical Africa, including Senegal [28]. The clinical signs in the dog are erythematous nodular lesions of varying dimensions with a central pore from which there is a bloody discharge; the end of the parasite is visible through the pore. *C. anthropophaga* is of great importance in public health, since it also causes myiasis in man, and it is recognised that dogs and cats may carry the infection into previously unaffected areas. The efficacy of selamectin in the control of canine cordylobiosis was investigated in Dakar, Senegal [28] where 85% of dogs carried one or more larvae. Dogs were treated at the standard dose-rate of 6 mg/kg. Treatment reduced the level of infestation to 0.1% by 10 days after the first treatment, and a similar low level of infestation was maintained throughout the remainder of the study, whilst 100% of dogs in the control group remained infested throughout the study.

**Discussion**

Selamectin has been commercially available for approximately seven years and in that time has become established as a useful and effective treatment for those conditions for which it is licensed, and also as a readily-applied treatment for a range of other endo- and ectoparasites. As a spot-on treatment it may be useful for cats, for which it may be difficult for owners to apply or administer other treatments.

The picture of the relationship between pharmacokinetic characteristics and efficacy is still emerging. The most recent contribution [29] to the understanding of the pharmacokinetics of topical selamectin was a study with topical treatment administered at the minimum recommended dose-rate. The investigators found greater availability of selamectin in female beagles than in male following topical administration at a dose-rate of 6 mg/kg.

Treatment in all the cases described in this paper has been apparently well-tolerated, even in the Japanese Chin dog treated daily at 30 mg/kg (5 × the minimum recommended label dosage administered daily instead of monthly) for two weeks [27]. This is not unexpected as selamectin has a favourable safety profile [6,7], and is well-tolerated by cats and dogs including ivermectin-sensitive collies [5].

**Competing interests**

The authors acknowledge the financial support of Pfizer Animal Health in conducting this review. Pfizer Animal Health provided the financial support to facilitate this review as a service to veterinarians in practice. Pfizer Animal Health does not endorse the use of selamectin other than in strict accordance with the product label.

DJS was an employee and consultant for Pfizer Animal Health for many years before retirement, and MAF has acted as consultant for Pfizer Animal Health on a number of projects.

**Authors’ contributions**

MAF and DJS participated in the drafting of the manuscript, in its revision for intellectual content and in the provision of references. Both authors read and approved the final manuscript.

**References**

1. Jacobs DE: Selamectin – a novel endectocide for dogs and cats. Vet Parasitol 2000, 91:161-162.
2. Blagburn BL: Changing trends in ectoparasite control. In Proceedings of the Fourth World Congress of Veterinary Dermatology. 30th August to 2nd September 2000; San Francisco Blackwell Science; 2002.
3. Campbell WC: Ivermectin and Abamectin Springer, New York; 1989.
4. Pulliam JD, Seward RL, Henry RT: Investigating ivermectin toxicology. Vet Med 1985, 80:33-40.
5. Bishop BF, Bruce CI, Evans NA, Goudie A, Gradon KAF, Gibson SP, Pacey MS, Perry DA, Walshe NDA, Witty MJ: Selamectin: a novel broad-spectrum endectocide for dogs and cats. Vet Parasitol 2000, 91:163-176.

6. Novotny MJ, Krautmann MJ, Ehrhart JC, Godin CS, Evans EL, McCall JW, Sun F, Rowan TG, Jernigan AD: Safety of selamectin in dogs. Vet Parasitol 2000, 91:377-391.
7. Krautmann MJ, Novotny MJ, De Keulenaer K, Godin CS, Evans EL, McCall JW, Wang C, Rowan TG, Jernigan AD: Safety of selamectin in cats. Vet Parasitol 2000, 91:393-403.
8. McTier TL, Jones RL, Holbert MS, Murphy MG, Watson P, Sun F, Smith DG, Rowan TG, Jernigan AD: Efficacy of selamectin against adult flea infestations (Ctenocephalides felis felis and Ctenocephalides canis) on dogs and cats. Vet Parasitol 2000, 91:187-199.
9. McTier TL, Shanks DJ, Watson P, McCall JW, Genchi C, Six RH, Thomas CA, Dickin SK, Pengo G, Rowan TG, Jernigan AD: Prevention of experimentally induced heartworm (Dirofilaria immitis) infections in dogs and cats with a single topical application of selamectin. Vet Parasitol 2000, 91:259-268.
10. Sarasola P, Jernigan AD, Walker DK, Castledine J, Smith DG, Rowan TG: Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. J Vet Pharmacol Ther 2002, 25:265-272.
11. Tarello W: Cutaneous lesions in dogs with Dirofilaria (Noctiella) repens infestation and concurrent tick-borne transmitted diseases. Vet Dermatol 2002, 13:267-274.
12. Pampiglione S, Canestri Trotti G, Rivas F: Human dirofilariasis due to Dirofilaria (Noctiella) repens: a review of world literature. Parasitologia 1995, 37:149-193.
13. Genchi C, Poglayen G, Kramer L et al.: Efficacy of selamectin in the prevention of Dirofilaria repens in dogs. Veterinaria (Cremona) 2002, 16:69-71.
14. Reinhart S, Ottenjann M, Schunack B, Kohn B: Lungworm disease (Aelurostrongylus abstrusus) in a cat. Kleintierpraxis 2004, 49:239-246.
15. Gaglio G, Cringoli G, Rinaldi L, Brianti E, Giglietto S: Use of Flotac technique for the diagnosis of Aelurostrongylus abstrusus in the cat. Parasitol Res 2005, 134:1055-1057.
16. Grandi G, Calvi LE, Venco L, Paratici C, Genchi C, Memmi D, Kramer LH: Aelurostrongylus abstrusus (cat lungworm) infection in five cats from Italy. Vet Parasitol 2005, 134:177-182.
17. Itoh N, Muraseka N, Aoki H, Isakagi T: Treatment of Noctodermatitis due to infestation in cats with selamectin. Vet Rec 2004, 154:404.
18. Leonie F, Albanease F, Fileccia I: La gale notoédrique du chat: à propos de 22 cas. Prat Méd Chir Anim Comp 2003, 38:421-427.
19. Gunnarsson L, Zakrisson G, Christenson D, Ugga A: Efficacy of selamectin in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs. J Am Anim Hosp Assoc 2004, 40:400-404.
20. Bowman DD: Georgis' Parasitology for Veterinarians. 6th edition. WB Saunders Company, Philadelphia, USA; 1995:72.
21. Chailleux N, Paradis M: Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats. Can Vet J 2002, 43(10):767-770.
22. Mueller RS, Bettenay SV: Efficacy of selamectin in the treatment of canine cheyletiellosis. Vet Rec 2002, 151:773.
23. Pancerée L, Cotteleeer C: Les Cheyletielles en Belgique. Observation d'une dermatose "à ch. Yasguri (Smiley 1965) chez l'homme et chez le chien. Schweiz Arch Tierheilk 1981, 123:601-604.
24. Leone F, Albanease F: Efficacy of selamectin spot-on formulation against Neotrombicula autumnalis in eight cats. Veterinary Dermatology 2004, 15(Suppl 1):49.
25. Scott DW, Miller WH, Griffin CE: Parasitic skin disease. Muller and Kirk's Small Animal Dermatology 6th edition. 2000.
26. Pfizer study number 1062E-60-97-235: Efficacy of 6 mg/kg UK-124,114 against Demodec canis on dogs. 1999, data on file.
27. Jeong H-H, Jeong A-Y, Hoh W-P, Eom K-D, Lee K-W, Oh T-H: Efficacy of weekly 0.1% amitraz dip with 4% chlorhexidine shampoo on juvenile onset generalised pyodermicosis unresponsive to ivermectin therapy in Japanese Chin Dog. Journal of Vet Clin 2003, 20:237-241.
28. Panguj L, Olloy A, Ndonide N, Cazin Ph: Cordylobiosis in dogs in Senegal: incidence and fight against infestation of dogs in Dakar. Revue de Médecine Vétérinaire 2003, 153:167-172.
29. Dupuy J, Darlon Al, Sutra JF, Cadiergues MC, Franc M, Alvinerie M: Pharmacokinetics of selamectin in dogs after topical application. Vet Res Commun 2004, 28:407-413.